Skip to content
HCN Grants Est. 2026
No. PAR-25-158 · National Institutes of Health
Open

Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)

Dealbreakers No cost share required Audit: not stated
Not reimbursement-only
“Grant: A financial assistance mechanism providing money, property, or both to an eligible entity to carry out an approved project or activity.” — From the announcement

At a glance

This program funds research on preventing fetal alcohol spectrum disorders and on interventions or treatments for people affected by prenatal alcohol exposure. It uses a two-part award: a 2-year R61 phase for initial development and proof of principle, followed by a 3-year R33 phase for further development, evaluation, and clinical utility if R61 milestones are met. Eligible applicants include a wide range of U.S. and foreign organizations, including nonprofits, colleges and universities, governments, small businesses, and faith-based or community-based organizations. No cost sharing is required. For the R61 phase, total direct costs may not exceed $350,000 over two years, with no more than $225,000 in any single year; for the R33 phase, direct costs may not exceed $500,000 per year. The notice is focused on prenatal alcohol exposure, though studies involving other prenatal substances may be considered responsive, and HIV/AIDS-only research and animal-only research are not responsive.

AI-generated summary — verify against the announcement

What it funds

  • Health
  • Research & Discovery
  • Other / needs-review
  • Biomedical & Disease Research
  • Maternal, Child & Reproductive Health
  • Public Health, Prevention & Nutrition
Official description from grants.gov

This Notice of Funding Opportunity (NOFO) focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this NOFO is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and the incidence of FASD and that (2) interventions for FASD. These objectives will be accomplished with the Exploratory/Developmental Phased Award (R61/R33) mechanism, clinical trial optional. The R61 phase will support pilot studies or secondary data analysis for hypothesis development and feasibility, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R61 phase. Highest priority will be given to applications with clinical trials. Applicants interested in planning clinical trials or adding to current projects may also consider NOFO (TEMP-23832, the R34 option).

Who can apply

  • City or township governments
  • County governments
  • For-profit organizations other than small businesses
  • Independent school districts
  • Native American tribal governments (Federally recognized)
  • Native American tribal organizations (other than Federally recognized)
  • Nonprofits with 501(c)(3) status (other than higher education)
  • Nonprofits without 501(c)(3) status (other than higher education)
  • Others
  • Private institutions of higher education
  • Public and State controlled institutions of higher education
  • Public housing authorities / Indian housing authorities
  • Small businesses
  • Special district governments
  • State governments
Geographic restriction None found in the announcement — likely nationwide